Popular Posts:
Recent Posts:
The overall ratings of three Medical Devices stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Hansen Medical (NASDAQ:HNSN) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Hansen Medical develops and manufactures medical robotics designed for positioning, manipulation, and control of catheters and catheter-based technologies. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum, Equity, Cash Flow, and Sales Growth, HNSN also gets F’s. The stock price has dropped 23.9% over the past month, worse than 1% increase the Nasdaq has seen over the same period of time. As of August 6, 16.7% of outstanding Hansen Medical shares were held short. For a full analysis of HNSN stock, visit Portfolio Grader.
Insulet‘s (NASDAQ:PODD) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Insulet is a medical device company that develops, manufactures and markets an insulin infusion system for people with insulin-dependent diabetes. The stock also gets an F in Equity. Investors seem to agree with the downgrade and have pushed down the share price 10.6% over the past month. As of August 6, 21.4% of outstanding Insulet shares were held short. For more information, get Portfolio Grader’s complete analysis of PODD stock.
This is a rough week for Syneron Medical (NASDAQ:ELOS). The company’s rating falls to D from the previous week’s C. Syneron Medical designs, develops, and markets aesthetic medical products based on proprietary Electro-Optical Synergy technologies. The stock gets F’s in Earnings Revisions, Equity, and Cash Flow. For a full analysis of ELOS stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Comments are currently unavailable. Please check back soon.